Mitral stenosis (MS)
occurring, on average, 20 years before presentation of mitral stenosis.
between the LA and LV, resulting in an icreased left atrial (LA) pressure. Hemodynamic changes (a rise in transvalvular pressure gradient) begin when the cross-sectional area of the valve, is reduced to less than 2 cm2.
Auscultatory findings in MS
The opening snap is an early diastolic sound of short duration, and it is considered as the most characteristic auscultatory finding of mitral stenosis (MS). You can hear the opening snap near the cardiac apex, but it is more easily heard along the lower left sternal border. However, as the disease progresses and the valve becomes more calcified and immobile, the opening snap may be lost. Also the first heart sound (S1), which is usually accentuated (loud) in MS, for the same reason can become softer at a later stage of the disease. The murmur of MS is a low-pitched rumbling mid-diastolic murmur. It is best heard with the bell of the stethoscope with the patient in the left lateral decubitus position. Presystolic accentuation of the murmur can be present if the patient is in sinus rhythm. Auscultation after a brief period of exercise usually accentuates the murmur of MS, because exercise increases the transvalvular gradient, due to the increased cardiac output and heart rate.
The length of the murmur correlates better with the severity of MS than the loudness. MS is more severe when the murmur is longer and when the time interval from the second heart sound (S2) to the opening snap is short.
The electrocardiogram (ECG) in MS, if the rhythm is sinus, shows left atrial enlargement. Atrial fibrillation may be present (it is common in MS). If pulmonary hypertension has developed, then there is also ECG evidence of right ventricular hypertrophy.
Echocardiography in MS
It shows structural abnormalities of the valve (in rheumatic MS mitral leaflets are thickened with abnormal fusion of their commissures). Echocardiography also shows restricted separation
Left atrial enlargement is also present.
The mitral valve area (MVA) can be measured directly from the parasternal short axis view at the level of the tips of the mitral valve. Optimal positioning of the echocardiographic view, in order to obtain this measurement, is done by first obtaining a parasternal long-axis view and placing the mitral valve orifice in the center of the scan plane. The transducer is then rotated 90° to obtain the short-axis view. Measurements are obtained at the tips of the mitral leaflets. Three-dimensional echocardiography can provide a more accurate determination of the mitral valve area (MVA).
MVA can also be calculated from Doppler velocity measurements (the diastolic pressure half time). In general, the pressure half time (PHT) represents the time in which the peak pressure gradient between two adjacent chambers decreases to the half of its value. Thus, the PHT is the time it takes for the pressure gradient across the valve to fall to one-half the starting value. (This is equal to the time for the velocity of the mitral E wave to decrease to 70% of peak velocity). The mitral inflow E wave is used in this calculation.
MVA (in cm2) = 220/PHT.
PHT is measured by tracing the deceleration slope of the E wave on a continuous wave Doppler recording of diastolic mitral ﬂow. In some cases, the deceleration slope can be bimodal with a more rapid decline of mitral ﬂow velocity in early diastole. Then it is recommended to trace the deceleration slope in mid-diastole rather than the early one.
Another method to determine the mitral valve area (MVA) is the PISA (proximal isovelocity surface area) method, a method also used (more commonly) for the calculation of the effective regurgitant oriffice in cases of mitral regurgitation. In mitral stenosis (MS) the PISA method can be used to calculate the MVA and it offers the advantage of being still accurate in case of concomitant mitral or aortic regurgitation.
On the atrial side of the stenotic mitral valve, diastolic flow converges towards the stenotic valvular orifice, producing multiple hemispheres of isovelocity (the velocity of blood is the same in every point of the surface of each of these converging hemispheres). As blood accelerates towards the stenotic orifice, the velocity at the outer hemispheres is lower than the velocity on the smaller inner hemispheres. If π=3.14, r (in cm) is the PISA radius (the radius of flow convergence) which is the radius of the hemisphere where blood velocity is the aliasing velocity and a is the opening angle of mitral leaflets, i.e. the angle between the two mitral leaflets at the atrial surface (in degrees), aliasing velocity is the velocity at which aliasing of color doppler occurs in the direction of flow through the mitral valve (this is set by the echocardiographer to 20-45 cm/s), then we can use the equation:
MVA= 2π r2 x (aliasing velocity/peak MS velocity) x (a/180).
MVA=6,28 r2 x (aliasing velocity/peak MS velocity) x (a/180)
Measurement of the opening angle is demanding, however it has
been demonstrated that there is only a slight difference in the angle
between patients and the use of a fixed angle of 100 degrees can provide an accurate estimation of MVA.
Current guidelines define clinically important, severe, MS as a valve area ≤1.5cm2 , because this valve area is typically accompanied by left atrial enlargement and elevated pulmonary artery systolic pressure. A valve area ≤1.0 cm2 is termed "very severe" MS.
Severe MS : mean gradient > 10 mm Hg.
Tricuspid regurgitation (TR) often accompanies severe MS. It may be secondary to right ventricular dysfunction and tricuspid annular dilation or may be the result of the rheumatic involvement of the tricuspid valve
Symptoms due to vascular congestion can be improved by restriction of salt intake and diuretic therapy.
Heart rate slowing agents, such as beta-blockers or nondihydropyridine calcium channel blockers (diltiazem or verapamil), increase diastolic left ventricular filling time and so they there decrease symptoms with exercise. These drugs, or digoxin, are also used to slow the ventricular rate in patients with rapid atrial brillation. Anticoagulant therapy to prevent thromboembolism is indicated in MS patients with atrial fibrillation, or an identied LA thrombus, or a prior embolic event.
Percutaneous or surgical valve interventions are the only treatments that alter the natural history of severe MS. They are indicated in patients with severe (see above for the echocardiographic criteria of MS severity), symptomatic MS. Percutaneous mitral balloon
valvuloplasty is the treatment of choice in appropriately selected patients (those without advanced anatomic deformity of the valve, and without moderate or severe mitral regurgitation, or left atrial thrombus). Transesophageal echocardiography (TEE) is indicated to exclude LA thrombus prior to valvuloplasty.
Percutaneous mitral valvuloplasty (PMV) is also indicated for asymptomatic patients with severe MS (valve area ≤1.5cm2) , who have pulmonary hypertension (pulmonary artery systolic pressure > 50 mm Hg at rest or > 60 mm Hg with exercise) if valve morphology is favorable for PMV, in the absence of left atrial thrombus or moderate to severe mitral regurgitation.
Mitral stenosis and echocardiography. A good video by 123sonography
Baumgarther H, et al. 2017 ESC/EACTS Guidelines for the management of valvular heart disease: The Task Force for the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS), European Heart Journal, , ehx391, https://doi.org/10.1093/eurheartj/ehx391